Correspondence 0001493152-24-035440 from IMPACT BIOMEDICAL INC. (IBO)
IMPACT BIOMEDICAL INC.
Date: Sept. 9, 2024 · CIK: 0001834105 · Accession: 0001493152-24-035440
AI Filing Summary & Sentiment
File numbers found in text: 333-275062
Letter
REVERE SECURITIES, LLC
Lexington Avenue, 16th Floor
New York, New York 10022
September 9, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, N.E.
Washington, DC 20549
Attention: Daniel Crawford
Re: Impact BioMedical Inc.
Registration Statement on Form S-1, as amended
File No. 333-275062
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Requested Date: Wednesday, September 11, 2024
Requested Time: 4:00 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, as representative of the underwriters of the proposed initial public offering of Impact BioMedical Inc. (the “Company”), hereby join the Company’s request that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Wednesday, September 11, 2024, or as soon thereafter as possible.
Pursuant to Rule 460 under the Securities Act, we hereby advise that we will distribute as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very
truly yours,
REVERE
SECURITIES, LLC
Show Raw Text
CORRESP
1
filename1.htm
REVERE
SECURITIES, LLC
560
Lexington Avenue, 16th Floor
New
York, New York 10022
September
9, 2024
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, N.E.
Washington,
DC 20549
Attention:
Daniel Crawford
Re:
Impact BioMedical Inc.
Registration
Statement on Form S-1, as amended
File
No. 333-275062
REQUEST
FOR ACCELERATION OF EFFECTIVENESS
Requested
Date: Wednesday, September 11, 2024
Requested
Time: 4:00 p.m., Eastern Time
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, as representative of the underwriters
of the proposed initial public offering of Impact BioMedical Inc. (the “Company”), hereby join the Company’s request
that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:00 p.m.,
Eastern Time, on Wednesday, September 11, 2024, or as soon thereafter as possible.
Pursuant
to Rule 460 under the Securities Act, we hereby advise that we will distribute as many copies of the proposed form of preliminary prospectus
as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The
undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange
Act of 1934, as amended.
Very
truly yours,
REVERE
SECURITIES, LLC
By:
/s/
Bill Moreno
Name:
Bill
Moreno
Title:
Chairman
& CEO